Gilead to support generic lenacapavir in low-income nations
Earlier this month, Gilead Sciences announced that it had signed non-exclusive, royalty-free voluntary licensing agreements…
Posted inInternational News PrEP Prevention
Concern as PrEP supplies run low in Australia
Australian sexual health and HIV organisations are sending out reminders for PrEP users to "plan…
Posted inHealthcare International News PrEP Prevention
PrEP approved to prevent HIV in Japan
Japan has approved the use of Truvada (TDF/FTC), sold by Gilead Sciences under the brand name Truvada, as PrEP for the prevention of HIV in the country.
Posted inInternational News Sexual Health
New virulent MPOX strain emerges: Latest info from UK organisations
Following the death of 524 people in the Democratic Republic of Congo The World Health…
Posted inCampaigning Criminalisation Human Rights News
Man living with HIV, caught in a Grindr sting, freed from Qatar
Manuel Guerrero Aviña, a British-Mexican man living with HIV, who was arrested in a Grindr…
Posted inNews PrEP Prevention
UK’s first Digital PrEP service starts in East Sussex
A new digital PrEP service has just launched in East Sussex, making it easier for…
Posted inConferences News Research Treatment
HIV viral rebounds following CRISPR gene therapy
EBT-101, a gene-editing therapy utilising CRISPR technology, showed promising safety and tolerability in an initial…
Posted inHealthcare Medicines News Parenting PrEP Prevention Research
Cabotegravir PrEP injection is safe during pregnancy
The safety and tolerability of long-acting injectable cabotegravir (CAB-LA) as HIV pre-exposure prophylaxis (PrEP) for…
Posted inConferences Cure News Treatment
Man “likely cured” of HIV after stem cell transplant
A new case of prolonged HIV remission was reported during the 25th International AIDS Conference…
Posted inConferences Healthcare Medicines News PrEP Prevention
Twice-yearly lenacapavir injection sees zero HIV infections in trial
AIDS 2024 Conference Coverage Preliminary findings from the phase III PURPOSE 1 trial revealed that…